Antibody Drug Conjugates in Glioblastoma – Is There a Future for Them?

Sagun Parakh1,2,3, Joseph Nicolazzo4, Andrew M Scott2,3,5,6 and Hui Kong Gan1,2,3,5*

1 Department of Medical Oncology, Austin Hospital, Heidelberg, VIC, Australia, 2 Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, VIC, Australia, 3 School of Cancer Medicine, La Trobe University, Heidelberg, VIC, Australia, 4 Drug Delivery, Deposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia, 5 Department of Medicine, University of Melbourne, Heidelberg, VIC, Australia, 6 Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, VIC, Australia

Glioblastoma (GBM) is an aggressive and fatal malignancy that despite decades of trials has limited therapeutic options. Antibody drug conjugates (ADCs) are composed of a monoclonal antibody which specifically recognizes a cellular surface antigen linked to a cytotoxic payload. ADCs have demonstrated superior efficacy and/or reduced toxicity in a range of haematological and solid tumors resulting in nine ADCs receiving regulatory approval. ADCs have also been explored in patients with brain tumours but with limited success to date. While earlier generations ADCs in glioma patients have had limited success and high toxicity, newer and improved ADCs characterised by low immunogenicity and more effective payloads have shown promise in a range of tumour types. These newer ADCs have also been tested in glioma patients, however, with mixed results. Factors affecting the effectiveness of ADCs to target the CNS include the blood brain barrier which acts as a physical and biochemical barrier, the pro-cancerogenic and immunosuppressive tumor microenvironment and tumour characteristics like tumour volume and antigen expression. In this paper we review the data regarding the ongoing development of ADCs in glioma patients as well as potential strategies to overcome these barriers to maximise their therapeutic potential.

Keywords: antibody drug conjugates (ADC), glioma, glioblastoma, blood brain barrier, tumour microenvironment, biomarkers, molecular imaging

INTRODUCTION

Glioblastoma (GBM) is an aggressive fatal disease characterised by complex molecular heterogeneity and aggressive infiltrative growth. Despite s decades of trials testing novel agents, the median survival remains unchanged at 14 - 17 months only (1–4). Multiple strategies have been explored with limited success to improve the efficacy of chemotherapy in GBM, including novel formulations, direct administration into the central nervous system (CNS) and targeted vascular disruption; unfortunately, these have often resulted in higher toxicity rates without significantly improving patient outcomes (5–7).
Antibody drug conjugates (ADCs) are a new but proven class of highly potent therapeutics, composed of a monoclonal antibody which specifically recognizes a cellular surface antigen linked to a cytotoxic payload (8). This results in a number of advantages: reduced toxicity due to more targeted delivery of cytotoxic therapy directly into the tumours; enhanced cell kill from the ability of use more toxic drugs that cannot be safely administered systemically; and the additive/synergistic benefit of combined tumour kill from the antibody and the payload respectively (9, 10). The ultimate efficacy of ADCs though relies on the complex interplay between three vital components: antibody, linker and payload. Early failures in the development of ADCs were due in part to challenges associated with these components, however recent advances have resulted in notable successes, resulting in nine ADCs receiving regulatory approval by the Food and Drug Administration in the USA and four ADCs by the European Medicines Agency (8, 11).

ADCs have also been explored for patients with brain tumours but with limited success to date. In particular, the apparent failure of two recent high-profile ADCs has resulted in a lessening of interest to this approach in glioma patients currently (12, 13). In this article, we will review the development of ADCs in glioma patients and summarise the data supporting their on-going development. We will discuss potential strategies to maximise their therapeutic potential by increasing their penetration through the blood-brain barrier (BBB), selection of more biologically relevant targets in the brain and its microenvironment, novel methods of drug targeting, newer payloads and better patient selection.

## EARLY ADCs IN GLIOMA THERAPY

The first generation of ADCs tested in glioma patients comprised mainly immunotoxins and radioimmunotherapy (Table 1). Immunotoxins are antibodies conjugated to naturally occurring bacterial toxins, such as Pseudomonas aeruginosa exotoxin A and diphtheria toxin. Radioimmunoconjugates utilise isotopes such as iodine-125 or iodine-131 as payloads. These commonly targeted the EGFR axis (either the receptor itself or its mutants and ligands) due the relatively high prevalence of these targets in gliomas and their likely role as an oncogenic pathway in glioma. Targeting the EGFRvIII mutation was particularly attractive. This is comprised of an in-frame deletion of exons 2-7 that results in a truncated by constitutively active receptor (24). Furthermore, the EGFRvIII mutation is relatively frequent (in 20-40% of GBM tumours) but shows a tumour restricted expression pattern compared to wildtype EGFR (24). However,

### TABLE 1 | Selected ADCs, immunotoxins and radioimmunoconjugates in high grade gliomas.

| Drug | Class | Phase | Date | Toxocities | Efficacy | Comments |
|------|-------|-------|------|-----------|----------|----------|
| ABT-414 | Anti-EGFR ADC with MMAF | I | 2015 | Lymphopenia, ocular toxicity, brain oedema, increased transaminases | Monotherapy: RR 8%, mOS N/A, PFS-6 24% | Data in EGFR amplified. Phase 2 and 3 studies in progress |
| AMG-595 | Anti-EGFR ADC with DM1 | I | 2014 | Thrombocytopenia, LFT abnormalities | RR 8%; mOS N/A; PFS-6 N/A |
| Cintredecin | IL13-PE38QQR | III | 2010 | Pulmonary embolism (8% including one fatal) | RR N/A; mOS 11.3 months; PFS-6 N/A |
| NBI-3001 | Circularized IL4-PE38KDEL | I/II | 2003 | Neurological deficits (Weakness, aphasia, confusion, coma), seizures, headaches, cerebral oedema, nausea, meningitis | RR N/A; mOS 5.8 months; PFS-6 6.48% |
| TP-38 (IVAX) | TGFrα + PE38 | I | 2008 | Fatigue, neurological deterioration (seizures, hemiparesis) | RR 13%; mOS 5 months; PFS-6 N/A |
| TI-CRM107 | Transferrin-DT | II | 2003 | Cerebral oedema, seizures | RR 35%; mOS 9 months; PFS-6 N/A | Phase 3 studies were aborted or remain unreported (20) |
| 125I-Mab | IV murine anti-EGFR (with RT-TM2) | II | 2010 | Occasional nausea, flushing, hypotension, skin irritation. Only 4 pts had HAMA | RR N/A; mOS 20.4 months | A sequential cohort with RT alone had mOS 10.2 months |
| 131I-81C6 | LR murine anti-tenasin (with RT-chemo) | Pilot | 2008 | Seizures (including status epilepticus), haematological, neurological, infective, thrombotic | RR N/A; mOS 22.6 months |
| 131I-BC2/BC4 | LR murine anti-tenasin (with conventional surgery and post-operative treatment) | I/II | 1999 | Headaches, HAMA reactions | RR N/A; mOS 19 months | Data shown for GBM patients; mOS was 25 months in small volume disease |

ADC, Antibody drug conjugate; EGFR, Epidermal growth factor receptor; HAMA, human anti-mouse antibody; LFTs, liver function tests; mOS, median overall survival; mPFS, median progression free survival; N/A, Not Available, RR, Response rate; RT, Radiotherapy; TMZ, temozolomide.
other targets of these early ADCs included IL-13Rα2 receptor, IL4 and transferrin. Unfortunately, these early ADCs were found to be ineffective due to a number of problems including high immunogenicity, unstable linkers, inefficient deliver due via early convection delivery systems, biomarker limitations to address tumour heterogeneity and toxicity (25–27).

NEWER ADCs IN NON-GLIOMA THERAPY

Subsequently, improved ADCs were generated which were characterised by low immunogenicity (usually with chimeric, humanised or fully human antibodies) and more effective payloads (Table 2). The success of these newer generation ADCs has been shown in haematological as well as in triple negative breast cancer (TNBC). These include brentuximab vedotin, an anti-CD30, antibody conjugated with monomethyl auristatin E (MMAE), an auristatin payload which disrupts microtubules. This has been shown to improve patient outcomes as consolidation after autologous stem cell transplant in patients with Hodgkin’s lymphoma (37), and the subsequently in combination therapy with chemotherapy in newly diagnosed patients (38). It has also been shown to be effective in patients with CD30-positive T-cell lymphoma (39, 40) and anaplastic large cell lymphoma (41). Trastuzumab emtansine, which carries also a microtubule targeting payload, DM1, has shown efficacy in patients with HER2-positive breast cancer and is the first ADC to be approved in solid tumors (42, 43). Other examples of successful ADCs utilising DNA-damaging payloads include inotuzumab ozogamicin with a calicheamicin payload in CD-22 positive ALL (44) and gemtuzumab ozogamicin with a calicheamicin payload in AML (45). Another highly promising class of payloads are those targeting topoisomerase, such as Sacituzumab govitecan (SG) against Trop 2 and bearing the SN38 payload. SG has shown significant activity in TNBC with improvements in PFS and OS compared to chemotherapy alone (46). In addition, SG has demonstrated activity in intracranial xenograft models and demonstrated activity in patients with recurrent GBM in a single centre pilot study (47).

NEWER ADCs IN GLIOMA THERAPY

In addition to their use in extra-cranial malignancies as described above, these newer ADCs have also been tested in glioma patients with mixed results. As before, targeting EGFR remained highly attractive due to the high frequency of abnormalities in this pathway in high grade gliomas. Furthermore, several highly specific and novel antibodies against EGFR and EGFRvIII had been developed which promised more selective targeting. The monoclonal antibody 806 (mAb806) is a murine anti-EGFR antibody that selectively targets a cryptic epitope of the EGFR which is only exposed under certain conditions, including where wild-type EGFR is highly over-expressed, where there are autocrine loops and/or harbor there are specific mutations which expose the epitope e.g. the EGFRvIII deletion variant. As these conditions are essential tumour restricted, mAb806 and derivative constructs are also tumour restricted with no normal tissue binding. This in this way, there avoid the toxicity typically associated with other systemic EGFR drugs inhibitors (48, 49). ABT-806, the humanized form of mAb806, has shown to be well tolerated and devoid of conventional anti-EGFR toxicities like rash and diarrhoea. Furthermore, biodistribution studies of 111In-ABT-806 showed no normal tissue uptake highlighting the tumor-specific nature of mAb806 (49–52). Depatuxizumab mafodotin (Depatux-M) is an EGFR targeting ADC comprising of mAb806

| Payload type         | Mechanism of action                                                                 | Common toxicities                                                                 |
|----------------------|--------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
| DM1                  | Inhibits tubulin polymerization and causes destabilization of microtubule structures | Thrombocytopenia, fatigue, increased levels of transaminases, anemia, nausea, hemorrhage, abdominal pain, pyrexia, musculoskeletal pain, vomiting, and dyspnea (28, 29) |
| DM4                  |                                                                                      |                                                                                   |
| MMAE                 |                                                                                      |                                                                                   |
| MMPF                 |                                                                                      |                                                                                   |
| Calicheamicin        |                                                                                      |                                                                                   |
| MMAF                 |                                                                                      |                                                                                   |
| Duocarmycin          |                                                                                      |                                                                                   |
| PBD                  | Prevents DNA unwinding by inhibition of DNA topoisomerase I resulting in irreversible double strand breaks | Hypocellular marrow, epistaxis, fatigue, thrombocytopenia, transaminisits, oedema, hypoalbuminemia, dyspnea (33) |
| SN-38                |                                                                                      | Thryphilitis, neutropenia, nausea, vomiting (36)                                  |

DM1, Mertansine/emtansine; DM4, Ravitansine/soravtansine; MMAE, Monomethyl auristatin E; MMAF, Monomethyl auristatin F; PBD, Pyrrolobenzodiazepine; SN38, Irinotecan metabolite.
linked to the anti-microtubule toxin monomethyl auristatin F (MMAF). Depatux-M has shown promising in-vivo activity in tumor models overexpressing wild type EGFR, EGFR amplification, or EGFRvIII mutation (53). Depatuxizumab mafodotin was also found to improve anti-tumour efficacy when combined with radiotherapy and temozolomide in preclinical models (53). The combination was also subsequently confirmed to be safe when tested in a Phase 1 study with newly diagnosed GBM with patients (54), and hence proceed to Phase 3 testing in the INTELLANCE I trial. Unfortunately, the addition of Depatux-M to standard chemoradiation with TMZ in newly diagnosed EGFR amplified glioblastoma patients was eventually discontinued for futility (12).

In contrast to the negative results in newly diagnosed patients, anti-EGFR ADCs targeting glioma with EGFR over-expression or EGFRvIII showed clear signals of efficacy in patients with relapsed glioma after chemo-radiation. Depatux-M was evaluated in the randomised phase II INTELLANCE 2 study in patients with EGFR amplified recurrent GBM (55, 56). In this study, the combination of Depatux-M with temozolomide (TMZ) demonstrated a strong trend towards substantial benefit in overall survival compared to the chemotherapy arm (HR 0.71, p=0.062) (57). The benefit of Depatux-M was highest in patients relapsing more than 16 weeks after the start of the last TMZ cycle. No evidence of efficacy in the monotherapy arm was observed in the subgroup with the MGMT promoter unmethylated tumors. These results are given added weight by the results of a Phase I/II study with AMG 595, an ADC comprising a fully human, anti-EGFRvIII monoclonal antibody linked via a non-cleavable linker to the maytansinoid DM1. AMG 595 has shown promising preclinical activity in assays including orthotopic murine models (58). In a phase I/II study of AMG 595 in patients with recurrent glioma expressing EGFRvIII (NCT01475006), the most common adverse events were thrombocytopenia (50%) and fatigue (25%); grade ≥ 3 treatment-related AEs occurred in 17 patients (53%). However, it is important to note that two patients had partial responses; 15 (47%) had stable disease, including one patient who was on treatment for 15 months (59). Unfortunately, development of this drug has also been discontinued.

FUTURE DIRECTIONS FOR THE DEVELOPMENT OF ADCs IN GLIOMA

The disappointing results of INTELLANCE 1 has rightly given pause and reconsideration to the role of ADCs in patients with gliomas. It has prompted reconsideration of reason why ADCs may not be suitable for use in patients with gliomas, including the relatively high toxicity when targeting the EGFR family with certain payloads, and the concern that these drugs are unable to penetrate the blood brain barrier to reach glioma tumour cells. One key concern is whether the results of INTELLANCE 1 should be allowed to overshadow the results of INTELLANCE 2 and the AMG-595 study. Much data suggest that recurrent gliomas are different disease from newly diagnosed GBM with changes in its genetic and molecular phenotype (60–66). While the further development of Depatux-M has been terminated by the company, the results of the INTELLANCE 2 study are intriguing about the possible use of this class of ADCs based on the mAb806 antibody particularly when compared to other drugs tested in GBM, such as immunotherapy, which have been universally disappointing in their lack of efficacy (Table 3).

In addition, suppression of EGFR or expression of an EGFR variant lacking the binding epitope and upregulation of compensatory signaling pathways associated with altered EGFR expression and known to function in parallel or downstream from EGFR were identified as potential mechanisms of resistance to Depatux-M.

Improved Drug Delivery Through BBB

One of the main reasons for the ineffectiveness of therapeutic agents intended to target the CNS following peripheral administration is the restrictive nature of the BBB. The BBB is formed by endothelial cells, connected by tight junctions, which continuously interact with surrounding cells like astrocytes, pericytes, and perivascular macrophages, forming the so-called neurovascular unit (78). Primary brain tumors, in particular glioblastoma, cause disruption in the integrity of the BBB as evidenced by the accumulation of gadolinium-based magnetic resonance imaging (MRI) contrast agents within tumor regions. However this disruption is heterogeneous and there is also a clinically significant portion of the tumor with an intact BBB which affects the distribution and efficacy of drugs exposed to this region of the tumor (79). Disrupting the BBB more completely would clearly be useful for treating gliomas with ADCs, amongst other drugs. There has also been recent interest in chemical-induced BBB disruption which has led to increased CNS exposure of ADCs. For example, NEO110, which is a high purity version of the natural monoterpene perillyl alcohol, has been shown to increase the brain delivery of T-DM1 in a mouse model harbouring intracranial HER2+ breast cancer, leading to a significantly greater survival (80). The clinical translation of BBB-disruptors such as NEO110 requires evaluation before such an approach may be considered appropriate for enhancing ADC penetration into the human brain.

In addition to being a physical barrier, the BBB also acts as a biochemical barrier through the function of efflux transporters, such as P-glycoprotein (P-gp) (81) and breast cancer resistance protein (BCRP) (82). While these efflux transporters protect the brain from potentially harmful xenobiotics, they recognise many therapeutics, including a large number of anti-cancer drugs, therefore, limiting their access to the CNS (83). In addition,
elimination of the cytotoxic payloads from the cellular cytoplasm by the ATP-binding cassette (ABC) transporters contribute to lower efficacy and resistance to ADCs (26). Increased MDRI expression has shown to contribute to resistance to auristatin and maytansinoids based ADC analogues, leading to poorer patient outcomes (84, 85). Strategies to overcome drug efflux from cells include using agents that are poor efflux substrates such as hydrophilic compounds or switching from a non-

**TABLE 3 |** Selected trials of therapeutic agents tested in glioma.

| Class of drugs | Setting | Trial Description | Target | Phase | NCT | Response rate | OS (months) | Toxicity |
|----------------|---------|------------------|--------|-------|-----|--------------|-------------|---------|
| **Immunotherapy** | Neoadjuvant | Neoadjuvant Nivolumab in Glioblastoma | PD-1 | II | NCT02550249 | No clinical benefit was substantiated following salvage surgery | NR |
| Pembrolizumab | Neoadjuvant anti-PD-1 immunotherapy in recurrent glioblastoma | PD-1 | Pilot | | NCT01588769 | DCR 50%* | NR |
| **Autologous lymphoid effector cells specific against tumor cells (ALECSAT)** | | | | | | | |
| CART-cell therapy | Anti- interleukin-13 receptor alpha 2 chimeric antigen receptor (CAR) T-cells | IL13Rα2 | I | | NCT00730613 | NR |
| CART-cell therapy | CMV-specific cytotoxic T lymphocytes expressing CAR targeting HER2 (HERT-GBM) | HER2 | I | | NCT01109095 | DCR 50% | 11.1 |
| IMA950 multi-peptide vaccine + poly-I:CLC | Trial of IMA950 Multi-peptide Vaccine Plus Poly-I:CLC | Human leukocyte antigen (HLA)-A2 restricted peptides | I/II | | NCT01920191 | DCR 42% | 19 |
| **Monoclonal antibodies** | | | | | | | |
| Onartuzumab | Onartuzumab in Combination With Bevacizumab Compared to Bevacizumab Alone or Onartuzumab Monotherapy | c-MET | II | | NCT01632228 | 8.8 (Onartuzumab + Bevacizumab) vs 12.6 (Bevacizumab) | Grade ≤ 3 TRAEs: 38.5% (experimental arm) vs 35.9% (bevacizumab) |
| Tanibirumab | Trial to Evaluate the Safety of TTAC-0001 (Tanibirumab) | VEGFR-2 | II | | NCT03033524 | NR | NR |
| **Nanoparticles** | DNX-2401 for Recurrent Malignant Gliomas | Oncolytic adenovirus | | | NCT00805376 | Group A (n = 25): 20% of patients survived > 3 years Group B (n = 12) – NR | NR |

*10 of the 25 recruited patients were evaluable.
*17 patients included 10 adults and 7 children.

CAR-T cells, Chimeric Antigen Receptor (CAR) T-Cell Therapy; DLT, Dose limiting toxicity; GSC, glioma stem cells; NR, not reported; ORR, Overall response rate; TRAE, treatment related adverse event; VEGFR, vascular endothelial growth factor receptor.
cleavable linker to a protease cleavable and using newer design drugs such as bispecific and bipartatopic antibodies can increase cellular internalization (26). Another mechanism that affects the therapeutic effectiveness of ADCs involves defects in the internalization pathway and reduced cell surface trafficking (86). Following internalisation, degradation of ADCs in lysosomes may be impaired by reduced lysosomal proteolytic or acidification function and/or loss of lysosomal transporter expression, resulting in failure of cleavage of cytotoxic payload from ADCs (87). Loss of lysosomal transporter expression, e.g., SLC46A3 has also been reported as a mechanism of innate and acquired resistance to PBD and DM1 bearing ADCs (88). Other potential mechanisms of escape include selection pressure and downregulation of antigens, loss of antigen expression or mutations in antigen as well as presence of ligands for antigens and resistance to ADC and acquired or innate insensitivity to the payload.

With increasing insight into the biology of the BBB and the discovery of novel transporters for trafficking of endogenous compounds, there has been significant interest in attaching natural ligands of these transporter systems to chemotherapeutics to increase their CNS access. One such ligand is angiopep-2, a 19 amino acid peptide targeting the low-density lipoprotein receptor-related protein 1 (LRP1). This has been conjugated to paclitaxel, amongst other anticancer agents. This construct of angiopep-2 and paclitaxel (GRN1005) was shown to be safe and somewhat effective in patients with advanced solid tumours (89), and a subsequent Phase I study showed that GRN1005 had similar toxicity to paclitaxel and some activity in recurrent glioma (90). These techniques were then applied to antibodies, albeit with a modified version of angiopep-2 that also is considered to exploit LRP1 to traverse the BBB i.e. melanotransferrin. Administration of melanotransferrin-trastuzumab conjugate (BT2111) reduced the number of HER2+ breast cancer metastases in the brain (by 68%) with tumours being 46% smaller in BT2111 treated mice relative to control mice (91). To the authors knowledge, there have been no studies where either Angiopep-2 or melanotransferrin have been conjugated to ADCs for the purposes of increasing CNS access, however, based on the results with trastuzumab, it is expected that utilising these shuttle protein approaches should result in increased ADC brain uptake and efficacy.

Lastly, drug penetration into tumours is not just impacted by the BBB. Physico-chemical properties such as tumour volume could be modulated to increase ADC penetration. Larger tumours have increased interstitial pressures, more impaired circulation/lymphatics and increased necrotic areas that limit the ability of ADCs to penetrate the tumours (92–94). Data from the M12-356 Phase I study of Depatux-M provides evidence of this problem in glioma patients (95). Preclinical imaging and biodistribution studies showed specific and significantly higher tumor uptake of zirconium-89 labelled Depatux-M (89Zr-Depatux-M) in mice with smaller tumor volume versus those with larger volumes. Concordantly, mice with smaller tumor volumes at treatment commencement had significantly better growth inhibition and significantly longer overall survival compared to mice with large tumors at treatment commencement. These findings were supported by an analysis of tumor volumes on outcomes in the M12-356 study; patients with large tumors had significantly worse response rates and overall survival. These findings strongly support strategies that would reduce tumor size and/or interstitial pressure to increase efficacy of ADCs in brain tumors (96–98). The tumour microenvironment (TME) in GBM is complex; it is characteristically immunosuppressive and made up of numerous cell types surrounded by a distinctive extracellular matrix (99). Dynamic changes in the cellular and metabolic composition within the TME can result in treatment resistant and tumor recurrence (100). Given the role of TME in tumor growth and blood vessel formation, strategies being investigated include targeting antigens of the TME instead of tumor specific antigens as well as overcoming the inherent immunosuppressive effects and making tumors more immune competent (99, 101, 102). Antigens of the TME are likely more accessible and targeting them allows ADCs to accumulate within tumors and release their payload based on TME-specific factors (103, 104). For example, CD25, CD205, B7-H3 are targets found in the TME for which specific ADCs are in clinical development in a number of non-CNS tumour types (105).

**Approaches to Reduce ADC Size/Polarity**

The antibody component of an ADC is vital for binding to the desired antigen with high affinity and specificity, maintaining a long half-life and releasing the toxic payload into tumor cells; however its large size presents a physical barrier to efficient extravasation across blood vessel walls and diffusion through tumors (106). This has led to the development of smaller formats as carriers of toxic payloads and include: antibody fragments, peptides, natural ligands, and small molecules (107). Several drug conjugates using smaller targeting domains are being evaluated in clinical trials (NCT02936323, NCT03221400, NCT03486730).

Aptamers are short single-stranded nucleic acids (RNA or ssDNA) that represent a novel imaging and drug-delivery strategy based on their sensitivity and specificity, ease of modification and low immunogenicity (108). Aptamers can be physically conjugated either by intercalating or covalent linking to novel therapeutics such as noncoding RNA or cytotoxic payloads like doxorubicin (109). Recent studies demonstrating the ability of aptamers to cross the BBB and deliver payloads to tumors (110) has resulted in considered interest in the potential role of aptamers in the management of gliomas. To date, several studies have evaluated the role of aptamer-based therapies as well as aptamer-based conjugates (non-coding RNA, nanoparticles, chemotherapeutics) in a number preclinical glioma models (111). The majority of studies targeted EGFR/EGFRvIII while others looked at other GBM-associated proteins including Tenascin-C, EphB2/3 receptors, nucleolin, vascular endothelial growth factor receptor (VEGF), and integrin a5b1 (108, 111). While the results in early preclinical studies are encouraging, further optimization of aptamers with regards to their sensitivity to body-fluid nucleases, CpG toxicity, and stability remain to be optimized.

Nanoparticles are promising carriers for drug delivery to the brain due to their unique characteristics which include their small size and specific and homogenous tumor targeting. Various
classes of nanoparticles, including metallic, polymeric and lipid nanoparticles can be readily modified to effectively carry drugs across the BBB. By attaching toxic payloads to nanoparticles, tumour-specific targets expressed in GBM cells and responsible for tumorigenesis can be targeted; examples of these include antigens (i.e., A2B5), differentiation clusters (i.e., CD15, CD33, CD44, or CD133), receptors of cytokines (i.e., interleukin13 receptor), and several proteins (i.e., EGFR, Integrin-a6, α5β3, αvβ3 or LIcam). An alternative to the classical antibody-drug conjugate is the antibody-mediated delivery of a drug containing nanoparticles. In a recent example, panitumumab/Vectibix was attached to a 400nm nanoparticle (minicell) derived from Salmonella typhimurium in the attempt to deliver an effective dose of doxorubicin to 14 patients with recurrent GBM (112). This study showed that EGFR targeting antibody-coated nanoparticles containing chemotherapeutic drugs could be delivered in recurrent GBM patients.

**ADCs Against Novel Targets**

Selecting an appropriate target antigen is a critical step for the success of an ADC. Ideally, the appropriate target antigen should tumor-specific and homogenous in expression. The ideal target is one which is strongly and homogenous expressed on tumor cells, absent on normal tissue and efficient internalisation when bound (113–115). The potency of ADCs is dependent on the ability of the antibody-antigen complex to internalize, release the payload within the target cells and exert the cytotoxic effect. This dependency on antigen expression levels and finite internalization limits the therapeutic potential of ADCs as well as contributes to off-target toxicities (27). Some strategies to overcome the requirement of internalisation include the targeting of non-internalising receptors and extracellular matrix targets. Furthermore, the identification of tumour microenvironment targets also raises the possibility of therapeutic approaches with ADCs which do not target tumor cells alone (8, 26, 115). Novel approaches to developing non-internalization ADCs include diabody-based ADCs against non-internalizing targets and anti-tumor angiogenesis ADC which have shown promise in preclinical studies (116, 117).

The cell surface Notch ligand delta-like 3 (DLL3) inhibits Notch pathway activation and has shown to be expressed on the cell surface of several tumor types including gliomas where DLL3 expression inversely correlated with outcome (118, 119). In brain tumors, DLL3 has been shown to be most intensely and homogeneously overexpressed in IDH-mutant gliomas compared to other glioma subtypes (120). Interestingly, in gliomas DLL3 overexpression is not a consequence of DLL3 mutations or gene amplification (120). DLL3 is not expressed in adult normal tissues (119), making it an attractive therapeutic target. Rovalpituzumab teserine (Rova-T; SC16LD6.5) is an ADC consisting of a monoclonal antibody targeting DLL3, a cathepsin-cleavable linker, and a PBD payload (119). The first-in-human clinical trial of Rova-T in small cell lung cancer (SCLC) demonstrated encouraging activity albeit significant toxicity related to the payload (121). The phase 3 study (TAHOE) in recurrent SCLC however was halted early due to futility (122). An active phase 3 trial of Rova-T in the maintenance setting (MERU) is ongoing (NCT03033511). In a phase 1/2 study (NCT02709889) patients with relapsed DLL3-positive (>1% by IHC) advanced solid tumors received Rova-T at 0.2, 0.3, or 0.4 mg/kg every 6-weeks for dose escalation in disease specific cohorts (123). The study enrolled 200 patients including 23 patients with GBM. The recommended phase 2 dose was 0.3 mg/kg q6wk for 2 cycles in all cohorts. The most common adverse events were fatigue, nausea, thrombocytopenia, pleural effusion and peripheral oedema. The objective response rate (ORR) was 11% including one complete response in the GBM cohort.

Increasingly, it is also becoming apparent that targeting the tumour microenvironment may be feasible in glioma and may have advantages over targeting tumours directly. Leucine-rich repeat containing 15 (LRRC15) is a type I membrane protein with low expression in normal tissue but is highly expressed on cancer associated fibroblasts within the tumor stroma as well as directly on cancer cells including GBM (124). ABBV-085 is an ADC composed of an anti-LRRC15 humanized monoclonal antibody conjugated to MMAE via a protease cleavable valine-citrulline linker. ABBV-085 has demonstrated significant antitumor activity in multiple LRRC15 cancer-positive models, including GBM. ABBV-085 also showed enhanced activity in combination with other therapies including cytotoxic chemotherapy, radiation, immunotherapy and targeted therapies (124).

Another promising target in the tumour microenvironment is the Eph family. Eph receptor tyrosine kinases and their cell-associated ephrin ligands have been implicated in the growth and progression of a large range of cancers and are increasingly recognized as important therapeutic anti-cancer targets (125). EphA2 and EphA3 are commonly expressed in GBM, including in regions of tumor neovascularure, tumor-associated immune cells, and tumor-infiltrating cells (126), and associated with poorer outcomes in GBM patients (127). MEDI-547 is an ADC comprising an EphA2 targeted monoclonal antibody (1C1) conjugated via a non-cleavable linker to the auristatin derivative maleimidocaproyl-monomethyl auristatin phenylalanine (mMMAF). MEDI-547 displayed encouraging antitumor activity in preclinical models (128) however clinical development was halted due to due to treatment-related adverse events during the early phase studies (129). Despite these results, given the overexpression of EphA2 in many tumor types targeting EphA2 for toxin delivery remains a promising therapeutic strategy. MM-310, an anti-EphA2 immuno-liposome containing docetaxel prodrug has shown superior tumor penetration and anti-tumor activity in a range of xenograft models compared to free docetaxel and significantly with lower toxicity (130). An ADC directed against EphA3, another member of this family, is also being pursued. An ADC based on the IIIA4 mAb, and utilizing the microtubule inhibitor maytansine (III A4-USAN), has highly effective in killing preclinical GBM models compared to the naked antibody (131). Similarly, anti-EphA3 bound nanoparticles loaded with the DNA alklylation agent temozolomide showed specific tumor targeting and potent anti-tumor effects in a rat glioma model (132). A phase 1 study of the Ifabotuzumab, the humanized version of IIIA4, has shown the drug is safe, is able to successfully target the tumour...
Novel ADCs With Improved Payloads

Coupled with the above strategies are strategies to utilise newer payloads with increased therapeutic ratios. A number of known issues can adverse impact ADCs. Linkers are an essential interface between antibody and drug payload and are critical in stability, site of conjugation and final drug/antibody ratio (DAR): parameters that impact on toxicity, efficacy and pharmacokinetic properties of ADCs (8, 30). Current linkers may release payloads in the circulation which can lead to off-target toxicity. The development of novel linkers and advances in linker technology is beyond the scope of this review but has been discussed elsewhere in detail (134, 135). In addition, the IgG1 isotype of some of these ADCs can engage the Fc-gamma receptors (FcγR), which can trigger a target-independent, FcγR-dependent internalization in FcγR-positive cells resulting in toxic effects on these untargeted healthy cells (136). In addition, each class of payload often has characteristics toxicities (Table 2). A number of newer payloads are being tested. Pyrrolobenzodiazepines (PBDs) are DNA–crosslinking agents that exert their biological activity by binding in the minor groove of DNA with enhanced potent anti-cancer activity compared to auristatins or maytansinoids (137, 138). PBD dimers exhibit significant cell permeability, potentially enabling bystander killing of neighboring tumor cells (139). A number of PBD-conjugated ADCs are being developed and in clinical trials for both solid and hematological tumors (140). For example, ABBV-321 (serclutamab talirine) is a highly selective next-generation EGFR-targeting ADC which incorporates a PBD dimer toxin conjugated to the EGFR-targeting ABT-806 affinity-matured AM1 antibody (10). It is expected that the highly selective nature of ABBV-321 would differentiate it from previously developed antibody PBD conjugates that lack a therapeutic window. In a number of xenograft cell line and patient-derived xenograft tumour models including in GBM, ABBV-321 exhibited potent anti-tumor activity (10). ABBV-321 is currently under clinical investigation in patients with advanced solid tumors (141).

Deruxtecan (DXd) is a potent topoisomerase I inhibitor with a short half-life and ability to elicit a bystander killing effect on neighboring tumour cells indicating low concern in terms of systemic toxicity and importantly may assist in overcoming intratumoral heterogeneity of cancer cells (142, 143). In addition to its by-stander effect, DXd is cell membrane permeable and therefore may enter nearby cells, even those without strong HER2 expression, making it effective in low HER2-expressing cancer cells and overcome tumour heterogeneity. Bioconjugation of DXd to a humanized monoclonal antibody specifically targeting HER2 via a cleavable tetrapeptide-based linker, made it possible to obtain the conjugate Trastuzumab Deruxtecan (DS-8201a, T-DXd) with a homogeneous DAR of 7.7. Trastuzumab deruxtecan has shown impressive response rates in early phase studies in tumours with high and low HER2 expression as well as HER2 mutant cancers (144, 145). The most common side effects were gastrointestinal and haematological, however potentially fatal adverse event of interstitial lung disease (ILD) was reported in 13.6% of patients in the phase II trial, including four patients who died due to lung injury (146). The mechanism of lung injury is not well understood and predictive biomarkers for response as well as identifying patients at risk of developing toxicity lung injury are required. Another ADC carrying the DXd payload is patritumab deruxtecan which uses the same linker-payload system as trastuzumab deruxtecan and is conjugated to the anti-HER3 monoclonal antibody patritumab. In a phase I study, patritumab deruxtecan demonstrated impressive responses in patients who were heavily pretreated with a median number of four regimens, including EGFR targeting tyrosine kinase inhibitors (147). Notably, its efficacy is observed regardless of the resistance mechanisms for EGFR-TKIs, including C797S secondary EGFR mutation, MET amplification, HER2 mutation, BRAF fusion, and PIK3CA mutation (147).

Lastly, there is on-going interest in utilising new radioisotopes in antibody payload delivery. Both the EphA2 mAb I77 coupled to Lutetium-177 and then anti-EphA3 antibody IIIA4 linked to an α-particle-emitting Bismuth-213 payload showed therapeutic effect in EphA2 and EphA3 expressing leukemia models (148, 149). In GBM models, treatment with IIIA4 labelled with the β-particle-emitting Lutetium-177 showed dose-dependent tumor cell killing and tumor growth inhibition in vivo, compared to unlabelled antibody (150).

Combinatorial Treatment Approaches to Address Heterogeneity and Resistance

Cancer cells are constantly under strong selection and evolutionary pressures, resulting in the emergence of subclones and heterogeneity in gene expression and antigen expression (151). This in turn can affect ADC efficacy which is correlated with the level of target antigen expression (114). In a phase II study, patients with early-stage HER2-positive breast cancer received six cycles of trastuzumab emtansine (T-DM1), in combination with pertuzumab in the neoadjuvant setting (152). In this study complete pathological response (pCR) was higher in those with HER2 scores of 3+ versus 2+ and no pCR was seen among the patients classified as having HER2 heterogeneity, indicating that heterogeneity of target antigen expression is an important factor in patient selection. GBM is characterised by significant heterogeneity even at the single cell level (153). Studies have reported substantial inter- and intra-tumoral variation in the levels of EGFR expression and mutation. Furthermore, EGFR mutations are frequently lost or gained between the initial tumor and recurrence while molecular alterations, such as EGFR amplification, remain persistent unchanged (60). Recently studies have also shown that EGFRvIII can be eliminated from extrachromosomal DNA of tumor cells as a resistance mechanism when tumor cells are treated with EGFR TKIs. However, upon drug removal, EGFRvIII reappears (154). Data from clinical studies suggest that substantial inter - and intra-tumoral variation in the levels of EGFR and EGFRvIII expression and mutation contribute to therapeutic resistance (155, 156).

Combinatorial approaches is one approach to address tumour heterogeneity and resistance in gliomas, and as already demonstrated improved responses and survival rates in other tumor types (157). Dual targeting of both wildtype EGFR and
EGFRvIII has been shown to have more effective anti-tumor activity in intracranial murine glioma models than single targeting of either variant alone (158). The anti-EGFR TKI AG1478 has shown to increase mAb 806-reactive dimers on the surface of cells overexpressing EGFR, and the combination has of mAb806 and AG1478 resulted in enhanced anti-tumour activity in xenograft models (159). Furthermore, Orellana et al. demonstrated that stabilizing the inactive kinase conformation with lapatinib correlated convincingly with increased binding of ABT-806 (160), further supporting the approach of targeting both EGFR and its variants.

Combinatorial strategies with ADCs may also effectively address the issue of tumour heterogeneity. Combining ABBV-321 and Deputax-M resulted in greater tumor growth inhibition in an EGFR-overexpressing GBM PDX model compared to either monotherapy treatment (161). It is also possible to incorporate two payloads into an ADC using multi-loading linkers, with improvements in conjugation efficiency and ADC homogeneity. Levengood et al. developed a dual-austatin ADCs containing both monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF) and showed superior therapeutic benefit in preclinical anaplastic large cell lymphoma models refractory to ADCs comprised of the individual auristatin components (162). Anami et al. developed an ADC composed of anti-HER2 antibody conjugated to the MMAF payload via branched linkers and compared with the ADC composed of linear linkers. Their results demonstrated compared to linear linkers, branched linkers were highly stable in the human plasma, having high cell specificity and antigen-binding efficiency, and more significant in vitro cell killing potency (163).

Immunogenic cell death of tumor cells induced by cytotoxic compounds used as payloads in ADCs can be potent stimulators of effector T-cell recruitment to tumors and can directly result in dendritic cell activation and maturation (164). Indeed, infiltration of T cells has been observed in tumor biopsy specimens from patients after treatment with ado-trastuzumab emtansine (T-DM1) (165). Based on the induction of antibody dependent cellular cytotoxicity (ADCC) by anti-HER2 therapies, preclinical studies addressed the potential synergistic effect of ado-trastuzumab emtansine (T-DM1) and ICIs. Preclinical studies have shown the combination of HER2-targeting ADCs with ICI resulted in curative responses despite primary resistance to immunotherapy model (166–168). Exploration of tumor specimens from patients enrolled on phase 1 study (M12-356, NCT01800695) (169) has revealed a significant association between T-cell activity and response to ABT-414 treatment (170). This raises the possibility that combination of ADCs with currently approved immunotherapy are very likely to be effective.

**Improved Patient Selection**

In order to maximize the therapeutic potential of ADCs and limit exposure of ADCs to patients unlikely to benefit, more sophisticated biomarkers to select patients are needed. The current strategy of identifying patients is based on tumor target expression, which can be challenging due to multiple factors including: tumor heterogeneity, assay sensitivity, and accuracy, potential changes in target expression after multiple therapies, and difficulties in determining threshold levels for target expression that correlate with efficacy (171). In most trials, patients are preselected based target expression on archival tumor tissue. The most commonly employed methodology to determine target expression is by immunohistochemistry (IHC) which does possess limitations including lacks standardisation, reproducibility and, most importantly, correlation with clinical outcome. For example, while antigen expression levels have shown to correlate with response, ADCs have also shown clinical activity in patients with low levels of target antigen expression cancers due to imperfect assays (144, 145). Furthermore, emerging data suggest that selection based on payload sensitivity may add additional value above simply target expression. In the phase 1 study (M12-356, NCT01800695) of Deputax-M in patients with newly diagnosed GBM and recurrent GBM with EGFR amplification, responses in patients with recurrent GBM correlated with EGFR amplification however not all patients with EGFR amplification responded (169).

**CONCLUSION**

ADCs have shown to be effective and safe therapies, expanding the armamentarium in several haematological and solid tumors and in many cases transforming treatment paradigms. To date,
their potential in glioma patients has not been established. Early ADCs were clearly ineffective due to limitations of early ADCs in general which affected their efficacy in all tumors. More recent ADCs like ABT-414 and AMG-595 clearly show the potential of these drugs in glioma, especially in recurrent gliomas. Clearly, more sophisticated strategies in their use will be needed if we are to make ADCs therapeutically useful for most glioma patients and to improve their therapeutic ratio. A number of such strategies are already available. Improvements in the ADC technology, building on the results of results to date, is clearly needed. These should focus on improvements in selecting targets and payloads. The use of adjunctive strategies is also appealing, seeking to improve drug access to tumors across the BBB and to better select patients. Lastly, combinatorial strategies are likely if we are to substantially improve outcomes in these patients and ADCs could have a major contribution to make in such strategies.

AUTHOR CONTRIBUTIONS
All authors contributed to conception and design of the review. All authors contributed to manuscript revision, read, and approved the submitted version.

FUNDING
We would like to acknowledge our funding sources including: the Cancer Council Victoria (grant No 1164229), the Victorian Cancer Agency (CRE in Brain Cancer and ECF Fellowship for SP), the Operational Infrastructure Support from the Victorian Government. The support of AMS (National Health and Medical Research Council Investigator Fellowship No 1177837) is also acknowledged.
57. Van Den Bent M, Eloi M, Sepulveda JM, Smits M, Walenkamp A, Frenel J-S, et al. INTELLIGENCE 2/EORTC 1410 Randomized Phase II Study of Deprazep-M Alone and With Temozolomide vs Temozolomide or
dLomustine in Recurrent EGFR Amplified Glioblastoma. Neuro-oncol (2020) 22(5):684–93. doi: 10.1093/neuco/not222

58. Hamblett KJ, Kozlowsky CJ, Sisu S, Chang WS, Liu H, Foltz IN, et al. AMG 595, an Anti-EGFRVIII Antibody Drug Conjugate, Induces Potent Anti-Tumor Activity Against EGFRVIII Expressing Glioblastoma. Mol Cancer Ther (2015) 14(7):1614–24. doi: 10.1158/1535-7163

59. Rosenthal M, Curry R, Reardon DA, Rasmussen E, Upreti VV, Damore MA, et al. Safety, Tolerability, and Pharmacokinetics of Anti-EGFRVIII Antibody–Drug Conjugate AMG 595 in Patients With Recurrent Malignant Glioma Expressing EGFRVIII. Cancer Chemother Pharmacol (2019) 84(2):327–36. doi: 10.1007/s00280-019-03879-2

60. Barthel FP, Johnson KC, Varn FS, Moskalik AD, Tanner G, Kocakavuk E, et al. Longitudinal Molecular Trajectories of Diffuse Glioma in Adults. Nature (2019) 576(7785):112–20. doi: 10.1038/s41586-019-17775-1

61. Eskilsson E, Verhaak RGW. Longitudinal Genomic Characterization of Brain Tumors for Identification of Therapeutic Vulnerabilities. Neuro-Oncol (2016) 18(8):1037–9. doi: 10.1093/neuonc/now064

62. Sottovia A, Spiteri I, Piccirillo SGM, Touloumis A, Collins VP, Marioni JC, et al. Intratumor Heterogeneity in Human Glioblastoma Reflects Cancer Evolutionary Dynamics. Proc Natl Acad Sci (2013) 110(10):4009–14. doi: 10.1073/pnas.1219747110

63. Kim J, Lee IH, Cho HJ, Park CK, Jung YS, Kim Y, et al. Spatiotemporal Evolution of the Primary Glioblastoma Genome. Cancer Cell (2015) 28(3):318–28. doi: 10.1016/j.ccell.2015.07.013

64. Johnson BE, Mazor T, Hong C, Barnes M, Aihara K, McLean CY, et al. Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma. Science (2014) 343(6167):189–93. doi: 10.1126/ science.1239947

65. Wang J, Cazzato E, Ladewig E, Frattini V, Rosenblom DI, Zairis S, et al. Clonal Evolution of Glioblastoma Under Therapy. Nat Genet (2016) 48(7):768–76. doi: 10.1038/ng.3590

66. Weller M, Butowski N, Tran D, Reck LD, Lim M, Hirté H, et al. Rindopepimut With Temozolomide for Patients With Newly Diagnosed, EGFRVIII-Expressing Glioblastoma (ACT IV): A Randomised, Double-Blind, International Phase 3 Trial. Lancet Oncol (2017) 18(10):1373–85. doi: 10.1016/neo.2017.02.068

67. Schalper KA, Rodriguez-Ruiz ME, Díez-Valle R, López-Janeiro A, Porciúncula A, Idoate MA, et al. Neoadjuvant Nivolumab Modifies the Tumor Immune Microenvironment in Resectable Glioblastoma. Nat Med (2019) 25(3):470–6. doi: 10.1038/s41591-018-0339-5

68. Keady DA, Kim T-M, Frenel J-S, Santono A, Lopez J, Subramanian DS, et al. ATM-35. Results of the Phase II KEYNOTE-028 Multi-Cohort Trial of Pembrolizumab Monotherapy in Patients With Recurrent PD-L1-Positive Glioblastoma Multiforme (GBM). Neuro-Oncol (2016) 18(suppl_6):vi25–6. doi: 10.1093/neuonc/nov212.100

69. Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB, et al. Intratumoral and Systemic Immune Responses in Recurrent Glioblastoma. Nat Med (2019) 25(3):470–6. doi: 10.1038/s41591-018-0339-5

70. Kurzrock R, Gabrail N, Chandhasin C, Moulder S, Smith C, Brenner A, et al. Safety, Pharmacokinetics, and Activity of GRN1005, a Novel Conjugate of Maytansinoid Antibody Drug Conjugate AMG 595 in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O (6)-Methylguanine-DNA Methyltransferase Biomarker Analyses. J Clin Oncol (2017) 35(3):343–51. doi: 10.1200/JCO.2015.64.7685

71. Chen L, Nowak A, Lapropusol G, Lee WS, Lee SY, Shim SR, et al. ACTR-75. A Multicenter, 3-Arm, Open-Label, Phase IIA Clinical Trial to Evaluate Safety and Efficacy of Tanibirumab (VEGFR2 mAB), in Patients With Recurrent GBM Assessed With K-Trans and Initial Area Under the Gdolinium Concentration-Time Curve (IAMEG). Neuro Oncol (2017) 19 (Suppl 6).17. doi: 10.1093/neuonc/nox168.082

72. Lang FF, Conrad C, Gomez-Manzano C, Yang WA, Sawaya R, Weinberg JS, et al. Phase I Study of DXN-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma. J Clin Oncol (2018) 36(14):1419. doi: 10.1200/JCO.2017.75.8219

73. Marin B-M, Porath KA, Jain S, Kim M, Conage-Pough JE, Oh J-H, et al. Heterogeneous Delivery Across the Blood-Brain Barrier Limits the Efficacy of an EGFR-Targeting Antibody Drug Conjugate in Glioblastoma. Neuro-Oncol (2021) 23(10):1656–67. doi: 10.1093/neuonc/noab294

74. Schinkel AH, P-Glycoprotein, a Gatekeeper in the Blood-Brain Barrier. Adv Drug Deliv Rev (1999) 36(2-3):179–94. doi: 10.1016/S0169-4099(98)00085-4

75. Niccolazzo JA, Katneni K. Drug Transport Across the Blood-Brain Barrier and the Impact of Breast Cancer Resistance Protein (ABCG2). Curr Topics Med Chem (2009) 9(2):130–47. doi: 10.2174/156802609787521580

76. Kim M, Kizilbash SH, Laramy JK, Gampa G, Parrish KE, Sarkaria JN, et al. Barriers To Effective Drug Treatment for Brain Metastases: A Multifactorial Problem in the Delivery of Precision Medicine. Pharmac Res (2018) 35(9):177–255. doi: 10.1007/s10928-018-04119-w

77. Loganzo F, Tan X, Sung M, Jinni H, Myers MI, Manduam E, et al. Tumor Cells Chronically Treated With a Trastuzumab–Maytansinoid Antibody–Drug Conjugate Develop Varied Resistance Mechanisms But Respond to Alternate Treatments. Mol Cancer Ther (2015) 14(4):952–63. doi: 10.1158/1535-7163.MCT-14-0862

78. Chen R, Hou J, Newman E, Kim Y, Dohoue C, Liu X, et al. CD30 Downregulation, MMAE Resistance, and MDRI Upregulation Are All Associated With Resistance to Brentuximab Vedotin. Mol Cancer Ther (2015) 14(6):1376–84. doi: 10.1158/1535-7163.MCT-15-0036

79. Sung M, Golas J, Wang F, King L, Myers J, Rosfjord E, et al. Caveolae-Mediated Endocytosis as a Novel Mechanism of Resistance to Trastuzumab Emtansine (T-DM1). Mol Cancer Ther (2018) 17(1):243–53. doi: 10.1158/1535-7163.MCT-17-0403

80. Rios-Luci C, García-Alonso S, Díaz-Rodríguez E, Nadal-Serrano M, Arribas J, Ocaña A, et al. Resistance to the Antibody-Drug Conjugate T-DM1 Is Based in a Reduction of Lysosomal Proteolytic Activity. Cancer Res (2017) 77(17):4639. doi: 10.1158/0008-5472.CAN-16-3127

81. Kinneer K, Meekin J, Tibergien AC, Tai Y-T, Phipps S, Kiever CM, et al. SLC46A3 as a Potential Predictive Biomarker for Antibody-Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads. Clin Cancer Res Off J Am Assoc Cancer Res (2018) 24(24):6570–8. doi: 10.1158/1078-0432.CCR-17-3189

82. Kurzrock R, Gribble N, Chandhaisin C, Moulder S, Smith C, Brenner A, et al. Safety, Pharmacokinetics, and Activity of GRN1005, a Novel Conjugate of Angiopep-2, a Peptide Facilitating Brain Penetration, and Paclitaxel, in
Patients With Advanced Solid Tumors. *Mol Cancer Ther* (2012) 11(2):308–16. doi:10.1158/1355-7186.MCT-11-0566

90. Drappatz J, Gallego A, Wong ET, Eichker A, Schiff D, Groves MD, et al. Phase I Study of GRN1005 in Recurrent Malignant Glioma. *Clin Cancer Res* (2013) 19(6):1567–76. doi:10.1158/1078-0432.CCR-12-2481

91. Nounou MI, Adkins CE, Rubinchik S, Terrell-Hall TB, Afozo M, Vitalis T, et al. Anti-Cancer Antibody Trastuzumab-Melanotransferrin Conjugate (BT2111) for the Treatment of Metastatic HER2+ Breast Cancer Tumors in the Brain: An In-Vivo Study. *Pharm Res* (2016) 33(12):2930–42. doi:10.1007/s11095-016-1305-3

92. Leu AJ, Berk DA, Lymboussaki A, Alitalo K, Jain RK. Absence of Functional Lymphatics Within a Murine Sarcoma: A Molecular and Functional Assessment of Existing Clinical Data. *Nat Rev Cancer* (2013) 13(1):44–54. doi:10.1038/nrc3445

93. Munson JM, Shieh AC. Interstitial Fluid Flow in Cancer: Implications for Disease Progression and Treatment. *Cancer Manag Res* (2014) 6:319. doi:10.2147/CMAR.S64444

94. Harder BG, Blomquist MR, Wang J, Kim AJ, Woodworth GF, Winkles JA, et al. Developments in Blood-Brain Barrier Penetration and Drug Repurposing for Improved Treatment of Glioblastoma. *Front Oncol* (2018) 8:462. doi:10.3389/fonc.2018.00462

95. Gan H, Seow A, Lau E, Sze-Ting L, Ameratunga M, Perchyonok Y, et al. ACTR-2G, A Novel Therapeutics and Potential Role in Neuro-Oncology. *Cancers* (2019) 11(10):2889. doi:10.3390/cancers11102889

96. Boni V, Sharma MR, Patnaik A. The Resurgence of Antibody Drug Conjugates: Opportunities and Challenges. *Antibody Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review*. *Adv Ther* (2017) 34(5):1015–35. doi:10.1007/s12265-017-0519-6

97. Perez EA, Hurvitz SA, Amrler LC, Mundt KE, Ng V, Guardino E, et al. Relationship Between HER2 Expression and Efficacy With First-Line Trastuzumab Emtansine Compared With Trastuzumab Plus Docetaxel in TDM4450g: A Randomized Phase II Study of Patients With Previously Untreated HER2-Positive Metastatic Breast Cancer. *Breast Cancer Res* (2014) 16(3):1. doi:10.1186/1473-5344-16-3

98. Heldin CH, Rubin K, Pietras K, Östman A. High Interstitial Fluid Pressure: Will It Yield Novel Successful Therapies for Solid Tumors? *Nat Rev Cancer* (2014) 14(2):105–17. doi:10.1038/nrc3539

99. Leu AJ, Berk DA, Lymboussaki A, Alitalo K, Jain RK. Absence of Functional Lymphatics Within a Murine Sarcoma: A Molecular and Functional Assessment of Existing Clinical Data. *Nat Rev Cancer* (2013) 13(1):44–54. doi:10.1038/nrc3445

100. Abels ER, Maas SL, Tai E, Ting DT, Broekman ML, Breake

101. Drappatz J, Brenner A, Wong ET, Eichker A, Schiff D, Groves MD, et al. Phase I Study of GRN1005 in Recurrent Malignant Glioma. *Clin Cancer Res* (2013) 19(6):1567–76. doi:10.1158/1078-0432.CCR-12-2481

102. Ali S, Borin TF, Piranlioglu R, Affinito A, Artecchia M, Cavaleri C, Condorelli G. The Role of RNA and DNA Aptamers in Glioblastoma Diagnosis and Therapy: A Systematic Review of the Literature. *Cancers* (2020) 12(8):2173. doi:10.3390/cancers12082173

103. 55. Tumor Volume as a Predictor of Response to Anti-EGFR ADC ABT-414. *Neuro-Oncol* (2018) 20(suppl_6):s124. doi:10.1093/neo/ney148.s87

104. Mathur R, Weiner GJ. Picking the Optimal Target for Antibody-Drug Conjugates. *Anti-Cancer Antibody Trastuzumab-Melanotransferrin Conjugate (BT2111) for the Treatment of Metastatic HER2+ Breast Cancer Tumors in the Brain: An In-Vivo Study. Pharm Res* (2016) 33(12):2930–42. doi:10.1007/s11095-016-1305-3

105. Boni V, Sharma MR, Patnaik A. The Resurgence of Antibody Drug Conjugates: Opportunities and Challenges. *Antibody Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review*. *Adv Ther* (2017) 34(5):1015–35. doi:10.1007/s12265-017-0519-6

106. Sarkaria JN, Hu LS, Parney IF, Pafundi DH, Brinkmann DH, Laack NN, et al. Apoptamer Functionalization of Nanosystems for Glioblastoma Targeting Through the Blood–Brain Barrier. *J Med Chem* (2017) 60(10):4510–6. doi:10.1021/acs.jmedchem.7b00527

107. Pomoni I, Camorani S, Colecchia D, Locatelli E, Calandro P, Oudin A, et al. Antibody Targeting of Ephrin-A2 in Brain Tumors: A Potentially Novel Therapeutic Strategy. *J Natl Cancer Inst* (2012) 104(18):2155–66. doi:10.1093/jnci/djs373

108. Blackhall F, Jao K, Greillier L, Cho BC, Penkov K, Reguart N, et al. Effect of Erlotinib on Lung Tumors: A Phase I Study of Tumors Through Simultaneous Ablation of CD276/B7-H3-Positive Tumor Cells and Tumor Vasculature. *Cancer Cell* (2017) 31(4):501–15. doi:10.1016/j.ccell.2017.03.005

109. Purcell JW, Tanlimco SG, Hickson J, Fox M, Sho M, Durkin L, et al. LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody-Drug Conjugate (ADC). *J Clin Oncol* (2018) 36(29):3131–40. doi:10.1200/JCO.2018.36.29.3131

110. Nagata S, Kuroda M, Usui M, Yamada T, Nonoyama T, Hamada T, et al. Anti-Cancer Antibody Trastuzumab-Melanotransferrin Conjugate (BT2111) for the Treatment of Metastatic HER2+ Breast Cancer Tumors in the Brain: An In-Vivo Study. *Pharm Res* (2016) 33(12):2930–42. doi:10.1007/s11095-016-1305-3

111.10.2147/CMAR.S64444

112. Parakh et al. Antibody Drug Conjugates in Glioblastoma
Implications for Combination Therapy With Monoclonal Antibody 806. J Biol Chem (2007) 282(5):2840–50. doi: 10.1074/jbc.M605136200

160. Orellana L, Thorne AH, Lema B, Gustavsson J, Parisian AD, Cordeiro TN, et al. Oncogenic Mutations at the EGFR Ectodomain Structurally Converge to Remove a Steric Hindrance on a Kinase-Coupled Cryptic Epitope. Proc Natl Acad Sci (2019) 116(20):10099–18. doi: 10.1073/pnas.1821442116

161. Anderson MG, Falls HD, Mitten MJ, Oleksijew A, Vaidya KS, Boghaert ER, et al. Targeting Multiple EGFR-Expressing Tumors With a Highly Potent Tumor-Selective Antibody-Drug Conjugate. Mol Cancer Ther (2020) 19 (10):2117–25. doi: 10.1158/1535-7163.MCT-20-0149

162. Leveggendorf MI, Zhang X, Hunter JH, Emmerton KK, Miyamoto JB, Lewis TS, et al. Orthogonal Cysteine Protection Enables Homogeneous Multi-Drug Antibody–Drug Conjugates. Angew Chem Int Edition (2017) 56(3):733–7. doi: 10.1002/anie.201608292

163. Anami Y, Xiong W, Gui X, Deng M, Zhang CC, Zhang N, et al. Enzymatic Conjugation Using Branched Linkers for Constructing Homogeneous Antibody–Drug Conjugates With High Potency. Org Biomol Chem (2017) 15(26):5635–42. doi: 10.1039/C7OB01027C

164. Gerber H-P, Sapra P, Loganzo F, May C. Combining Antibody–Drug Conjugates and Immune-Mediated Cancer Therapy: What to Expect? Biochem Pharmacol (2016) 102:1–6. doi: 10.1016/j.bcp.2015.12.008

165. Griguolo G, Pascual T, Dieci MV, Guarneri V, Prat A. Interaction of Host Immunity With HER2-Targeted Treatment and Tumor Heterogeneity in HER2-Positive Breast Cancer. J Immunother Cancer (2019) 7(1):1–14. doi: 10.1186/s40428-019-0548-6

166. Khattar M, Traore T, Horton K, Gallery M, Brauer P, Riceberg J, et al. Synergy of an Anti-HER2 ADC TAK-522 (XMT-1522) in Combination With Anti-PD1 Monoclonal Antibody in a Syngeneic Breast Cancer Model Expressing Human HER2. Cancer Res (2018) 78(13 Suppl):LB-294. doi: 10.1158/1538-7445.AM2018-LB-294

167. Müller P, Kreuzaler M, Khan T, Thommen DS, Martin K, Glatz K, et al. Trastuzumab Emtansine (T-DM1) Renders HER2+ Breast Cancer Highly Susceptible to CTLA-4/PD-1 Blockade. Sci Trans Med (2015) 7 (315):315ra188–315ra188. doi: 10.1126/scitransmed.aac4925

168. Ruo-Doria J, Harper J, Rothstein R, Wetzel L, Chesebrough J, Marrero A, et al. Antibody–Drug Conjugates Bearing Pyrrolobenzodiazepine or Tubulysin Payloads Are Immunomodulatory and Synergize With Multiple Immunotherapies. Cancer Res (2017) 77(10):2686–98. doi: 10.1158/0008-5472.CAN-16-2854

169. Reardon DA, Lassman AB, van den Bent M, Kumthekar P, Merrell R, Scott AM, et al. Efficacy and Safety Results of ABT-414 in Combination With Radiation and Temozolomide in Newly Diagnosed Glioblastoma. Neuro-Oncol (2017) 19(7):965–75. doi: 10.1093/neuonc/nox257

170. Lassman AB, Gan HK, Roberts-Rapp L, Ansell P, Merrell R, Kumthekar P, et al. (2017). Identifying the Correct Patient Population for Depatuxizumab Mafodotin (ABT-414): Biomarker Assays for Epidermal Growth Factor Receptor (EGFR) in Patients With Glioblastoma. In: World Federation of Neuro-Oncology. Zurich, 4-7 May, 2017.

171. Ileana Dumbrava E, Meric-Bernstam F, Yap TA. Challenges With Biomarkers in Cancer Drug Discovery and Development. Expert Opin Drug Discov (2018) 13(8):685–90. doi: 10.1080/17460441.2018.1479740

172. Lassman A, Roberts-Rapp L, Hu L, Xu Y, van den Bent M, Papadopoulos K, et al. PATH-29. Molecular Determinants Associated With Response and Resistance to Depatuxizumab Mafodotin (ABT-414) In Patients With Recurrent GLIOBLASTOMA. Neuro-Oncol (2017) 19(suppl_6):vi176–7. doi: 10.1093/neuonc/nox168.719

173. Scott AM, Lee F-T, Tabbett N, Herbertson R, Gill SS, Liu Z, et al. A Phase I Clinical Trial With Monoclonal Antibody Ch806 Targeting Transitional State and Mutant Epidermal Growth Factor Receptors. Proc Natl Acad Sci (2007) 104(10):4071–6. doi: 10.1073/pnas.0708144104

174. Gan HK, Burge M, Solomon B, Lee S, Holen KD, Zhang Y, et al. A Phase 1 and Biodistribution Study of ABT-806, An Indium-111 Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806. J Nucl Med (2021) 62(11). doi: 10.2967/jnumed.20.253146

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Parakh, Nicolazzo, Scott and Gan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.